Cargando…

Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage

Detalles Bibliográficos
Autores principales:	Arora, Prerna, Cossmann, Anne, Schulz, Sebastian R, Ramos, Gema Morillas, Stankov, Metodi V, Jäck, Hans-Martin, Behrens, Georg M N, Pöhlmann, Stefan, Hoffmann, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9815825/ https://www.ncbi.nlm.nih.gov/pubmed/36620969 http://dx.doi.org/10.1016/S1473-3099(22)00831-3

Ejemplares similares

Host cell entry and neutralisation sensitivity of the SARS-CoV-2 XBB.1.16 lineage
por: Nehlmeier, Inga, et al.
Publicado: (2023)

Profound neutralization evasion and augmented host cell entry are hallmarks of the fast-spreading SARS-CoV-2 lineage XBB.1.5
por: Hoffmann, Markus, et al.
Publicado: (2023)

Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5
por: Arora, Prerna, et al.
Publicado: (2022)

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination
por: Behrens, Georg MN, et al.
Publicado: (2021)

The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineages
por: Arora, Prerna, et al.
Publicado: (2022)

Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation
por: Hoffmann, Markus, et al.
Publicado: (2023)

Lung cell entry, cell–cell fusion capacity, and neutralisation sensitivity of omicron sublineage BA.2.75
por: Arora, Prerna, et al.
Publicado: (2022)

The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency
por: Arora, Prerna, et al.
Publicado: (2021)

Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
por: Arora, Prerna, et al.
Publicado: (2022)

Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance
por: Arora, Prerna, et al.
Publicado: (2021)

SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination
por: Arora, Prerna, et al.
Publicado: (2022)

Efficient antibody evasion but reduced ACE2 binding by the emerging SARS-CoV-2 variant B.1.640.2
por: Arora, Prerna, et al.
Publicado: (2022)

Host Cell Entry and Neutralization Sensitivity of SARS-CoV-2 Lineages B.1.620 and R.1
por: Sidarovich, Anzhalika, et al.
Publicado: (2022)

Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy
por: Jedicke, Nils, et al.
Publicado: (2021)

Omicron sublineage BQ.1.1 resistance to monoclonal antibodies
por: Arora, Prerna, et al.
Publicado: (2023)

The SARS-CoV-2 Delta-Omicron Recombinant Lineage (XD) Exhibits Immune-Escape Properties Similar to the Omicron (BA.1) Variant
por: Arora, Prerna, et al.
Publicado: (2022)

Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection
por: Carr, Edward J, et al.
Publicado: (2023)

Omicron sublineage recombinant XBB evades neutralising antibodies in recipients of BNT162b2 or CoronaVac vaccines
por: Zhang, Xiaojuan, et al.
Publicado: (2023)

No evidence for increased cell entry or antibody evasion by Delta sublineage AY.4.2
por: Arora, Prerna, et al.
Publicado: (2022)

B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination
por: Arora, Prerna, et al.
Publicado: (2021)

SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination
por: Hoffmann, Markus, et al.
Publicado: (2021)

XBB.1.5 an emerging threat: correspondence
por: Mohanty, Aroop, et al.
Publicado: (2023)

Omicron Sub-Lineage BA.5 and Recombinant XBB Evasion from Antibody Neutralisation in BNT162b2 Vaccine Recipients
por: Brandolini, Martina, et al.
Publicado: (2023)

Perceived versus proven SARS-CoV-2-specific immune responses in health-care professionals
por: Behrens, Georg M. N., et al.
Publicado: (2020)

SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies
por: Arora, Prerna, et al.
Publicado: (2022)

The SARS-CoV-2 Omicron recombinant subvariants XBB, XBB.1, and XBB.1.5 are expanding rapidly with unique mutations, antibody evasion, and immune escape properties – an alarming global threat of a surge in COVID-19 cases again?
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB
por: Uraki, Ryuta, et al.
Publicado: (2023)

Severity of SARS-CoV-2 Omicron XBB subvariants in Singapore
por: Pung, Rachael, et al.
Publicado: (2023)

ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5
por: Yue, Can, et al.
Publicado: (2023)

Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate
por: Uraki, Ryuta, et al.
Publicado: (2023)

Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB
por: Imai, Masaki, et al.
Publicado: (2022)

Recent update on XBB.1.5 emerging novel mutation of COVID-19
por: Amin, Ruhul, et al.
Publicado: (2023)

Neutralization of BQ.1, BQ.1.1, and XBB with RBD-Dimer Vaccines
por: Li, Dedong, et al.
Publicado: (2023)

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
por: Barros-Martins, Joana, et al.
Publicado: (2021)

Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant
por: Yamasoba, Daichi, et al.
Publicado: (2023)

Impact of SARS-CoV-2 envelope protein mutations on the pathogenicity of Omicron XBB
por: Wang, Yi, et al.
Publicado: (2023)

SARS-CoV-2 variant omicron XBB.1.5: challenges and prospects – correspondence
por: Channabasappa, Nikhil K., et al.
Publicado: (2023)

Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies
por: Yamasoba, Daichi, et al.
Publicado: (2022)

Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage
por: Gruell, Henning, et al.
Publicado: (2022)

Finite neutralisation breadth of omicron after repeated vaccination
por: Zhu, Yufang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mqgd3gupb0k3ie6aden92e3akr